Scrip
>>COVID-19

Coronavirus Update: Pfizer Vaccine Candidates Gain Fast-Track Status

Two mRNA Candidates Selected

14 Jul 2020

• By Scrip Team

The granting of fast-track status is a clear signal that the US FDA wants to maintain its high standards of drug and vaccine appraisal.

Face coverings will be mandatory in England's shops from 24 July, bringing it into line with Scotland and other European nations such as Spain, Italy and Germany.

Two of the four investigational COVID-19 vaccine candidates being developed by Pfizer Inc. and BioNTech have gained fast track designation from the US Food and Drug Administration.

The two candidates using the mRNA-based vaccine platform are BNT162b1 and BNT162b2 and are the most advanced in the partners’ ongoing Phase I/II clinical studies in the US and Germany....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

21 May 2025

• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

17 Feb 2025

• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

20 Jan 2025

• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

Stock Watch: Q3, Bonfire Of The Vaccine Manufacturers

13 Nov 2024

• By Andy Smith

Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.